We are live on ! Find out more
HALO icon

Halozyme

508 hedge funds and large institutions have $5.86B invested in Halozyme in 2024 Q4 according to their latest regulatory filings, with 66 funds opening new positions, 179 increasing their positions, 176 reducing their positions, and 84 closing their positions.

New
Increased
Maintained
Reduced
Closed

185% more call options, than puts

Call options by funds: $36.9M | Put options by funds: $12.9M

2% more repeat investments, than reductions

Existing positions increased: 179 | Existing positions reduced: 176

0% more funds holding

Funds holding: 508 → 508 (0)

2.54% less ownership

Funds ownership: 98.82% → 96.28% (-2.5%)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

21% less first-time investments, than exits

New positions opened: 66 | Existing positions closed: 84

23% less capital inflows, than outflows

Capital inflows: $613M | Capital outflows: $797M

Holders
508
Holders Change
–
Holders Change %
0%
% of All Funds
6.67%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.05%
New
66
Increased
179
Reduced
176
Closed
84
Calls
$36.9​M
Puts
$12.9​M
Net Calls
+$24​M
Net Calls Change
+$13.6​M

HALO Hedge Fund Activity: Q4 2024 in Review

508 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q4 2024, worth a combined $5.86B — down 18% from $7.16B a quarter earlier.

Sellers outnumbered buyers: 84 funds closed out of HALO and 66 opened new positions — a net loss of 18 holders — while 176 trimmed existing stakes and 179 added.

The largest buyer was Bank of America, adding an estimated $70.7M. The largest seller was Artisan Partners, cutting an estimated $90.3M.

  • 508 institutional investors held Halozyme (HALO) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $5.86B of Halozyme stock for Q4 2024, down 18% quarter-over-quarter.
  • 66 funds opened new Halozyme positions in Q4 2024 and 84 closed out, a net change of -18 holders.
  • The largest Halozyme buyer in Q4 2024 was Bank of America, an estimated $70.7M added.
  • The largest Halozyme seller in Q4 2024 was Artisan Partners, an estimated $90.3M sold.

Based on aggregated 13F filings for Q4 2024.